David Amsellem
Stock Analyst at Piper Sandler
(4.79)
# 113
Out of 5,113 analysts
164
Total ratings
65.19%
Success rate
23.38%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTRS Viatris | Maintains: Neutral | $9 → $12 | $12.97 | -7.48% | 8 | Jan 28, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | $62 → $66 | $54.62 | +20.83% | 2 | Jan 28, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $148 → $223 | $185.17 | +20.43% | 4 | Jan 16, 2026 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $18 | $7.46 | +141.29% | 1 | Jan 9, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $30 → $40 | $33.21 | +20.45% | 11 | Dec 22, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $147 → $219 | $165.41 | +32.40% | 15 | Dec 10, 2025 | |
| ESPR Esperion Therapeutics | Initiates: Overweight | $9 | $3.46 | +160.12% | 1 | Nov 25, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $118 → $157 | $174.83 | -10.20% | 3 | Nov 21, 2025 | |
| AMGN Amgen | Maintains: Overweight | $342 → $381 | $342.22 | +11.33% | 6 | Nov 14, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Overweight | $5 → $8 | $3.24 | +146.91% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $7.16 | +11.73% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $284 → $289 | $218.67 | +32.16% | 3 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $13.95 | -6.81% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $134.66 | +32.93% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $45 | $33.90 | +32.74% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $48.94 | +32.82% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $26.12 | -4.29% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $45.85 | +163.90% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $8.89 | +102.47% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $44.82 | -17.45% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $21.54 | -39.65% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $79.51 | -14.48% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.66 | -47.00% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $20.38 | +106.08% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $4.79 | +338.41% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $36.84 | +14.01% | 3 | Oct 16, 2023 |
Viatris
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $12.97
Upside: -7.48%
Bristol-Myers Squibb Company
Jan 28, 2026
Maintains: Overweight
Price Target: $62 → $66
Current: $54.62
Upside: +20.83%
Axsome Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $185.17
Upside: +20.43%
Fennec Pharmaceuticals
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $7.46
Upside: +141.29%
Teva Pharmaceutical Industries
Dec 22, 2025
Maintains: Overweight
Price Target: $30 → $40
Current: $33.21
Upside: +20.45%
Jazz Pharmaceuticals
Dec 10, 2025
Reiterates: Overweight
Price Target: $147 → $219
Current: $165.41
Upside: +32.40%
Esperion Therapeutics
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $3.46
Upside: +160.12%
Biogen
Nov 21, 2025
Reiterates: Neutral
Price Target: $118 → $157
Current: $174.83
Upside: -10.20%
Amgen
Nov 14, 2025
Maintains: Overweight
Price Target: $342 → $381
Current: $342.22
Upside: +11.33%
Aquestive Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $3.24
Upside: +146.91%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $7.16
Upside: +11.73%
Nov 5, 2025
Reiterates: Overweight
Price Target: $284 → $289
Current: $218.67
Upside: +32.16%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $13.95
Upside: -6.81%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $134.66
Upside: +32.93%
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $33.90
Upside: +32.74%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $48.94
Upside: +32.82%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $26.12
Upside: -4.29%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $45.85
Upside: +163.90%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $8.89
Upside: +102.47%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $44.82
Upside: -17.45%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $21.54
Upside: -39.65%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $79.51
Upside: -14.48%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.66
Upside: -47.00%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $20.38
Upside: +106.08%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $4.79
Upside: +338.41%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $36.84
Upside: +14.01%